U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE

MedGen UID:
1641090
•Concept ID:
C4684997
•
Finding

Recent clinical studies

Etiology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI
Ann Oncol 2020 Apr;31(4):532-540. Epub 2020 Feb 1 doi: 10.1016/j.annonc.2019.12.008. PMID: 32147213

Therapy

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI
Ann Oncol 2020 Apr;31(4):532-540. Epub 2020 Feb 1 doi: 10.1016/j.annonc.2019.12.008. PMID: 32147213

Clinical prediction guides

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI
Ann Oncol 2020 Apr;31(4):532-540. Epub 2020 Feb 1 doi: 10.1016/j.annonc.2019.12.008. PMID: 32147213

Supplemental Content

Table of contents

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...